Chemistry GIP consists of 43 amino-acid residues in a single chain, with a molecular weight of 5105 daltons. The amino-acid sequence is shown below. Residues which have been underlined correspond to sequence homologies with other members of the secretin-VIPglucagon family of peptides.
Tyrl-Ala-Glu-Gly-Thr5-Phe-Ile-Ser-Asp-Tyr10-Ser-Ile-Ala-Met-Asp15-Lys-Ile-Arg-Gln-Gln2O-Asp-Phe-Val-Asn-Trp25-Leu-LeuAla-Gln-G]n3k Lys-Gly-Lys-Lys-Ser35-Asp -Trp -Lys -HisAsn40-Ile-Thr-Gln Chromatographic analysis of jejunal extracts and of serum taken after a mixed meal has shown that GIP exists in more than one molecular form (Brown et al., 1975; Sarson et al., 1979) . Three distinct peaks of immunoreactive GIP have been shown (Fig. 1) .
(1) A high molecular weight fraction which occurs in the void volume. A significant reduction in this peak is seen following pretreatment of the *Now often referred to as glucose-dependent insulinotropic polypeptide.
sample with 8. 0 M urea. Thus, this peak may represent a protein/peptide complex. (2) A large molecular form which may correspond to either a 'big GIP' or a precursor pro-GIP.
(3) A 5000 dalton molecular form. This peak elutes in the same position as porcine standard and 1251-labelled GIP.
The exact nature and properties of these different molecular species require further analysis to determine which form or forms of GIP are biologically active.
On the basis of several amino-acid sequence homologies GIP has been placed in the classical secretin-glucagon-VIP family of peptides. Indeed these structural similarities are mirrored effectively in shared pharmacological activities. Examples of properties common to these substances are inhibition of gastric acid secretion and the in vivo and in vitro release of insulin.
CELLULAR LOCALISATION AND DISTRIBUTION
The availability of suitable antisera to GIP has made it possible to localise the GIP-containing cells by indirect immunofluorescence studies. Work reported in 1973 by Polak and colleagues tentatively identified the GIP cell as residing in the middle layer of the upper intestinal mucosa. Recently the site of anti-GIP antiserum activity has been shown to be the K cell, previously classified by electron microscopy according to the appearance of its granules (Buffa et al., 1975) .
Radioimmunoassay of GIP in extracts of homogenised gut tissue has confirmed these histochemical findings. Immunoreactive GIP (IR GIP) has been found to be distributed throughout the upper small intestine (Fig. 2) , with the greatest concentration in the jejunal mucosa (Bloom et al., 1975) .
MEAS UREMENT
The crude bioassay employed by Brown and coworkers in the course of purifying GIP is far too insensitive to detect the small quantities in the circulation released by physiological stimuli. This is only possible by the use of a sensitive and highly specific radioimmunoassay. Several such assays have been reported (Kuzio et al., 1974; Lauritsen and Moody, 1978; Morgan et al., 1978; Sarson et al., 1979) , but there appears to be little agreement between different authors with regard to basal and postprandial serum concentrations. In some cases ten-fold differences have been reported.
Several factors probably contribute to these differences. Primarily, the affinity of the antisera for each different molecular form of IR GIP needs to be determined, and also whether the forms measured reflect biological activity. Secondly, but of equal importance, are the difficulties arising from the poor antigenicity of GIP, and the need to conjugate it with a larger molecule. The latter procedure may lead to conformational damage to the molecule, resulting in subsequent problems in the assay. Moreover, the shortage ofpure GIP has led to the use of large amounts ofimpure preparations for the raising of antisera. The major consequence of this is the production of a heterogeneous population of antibodies with low specificity.
Another common difficulty is the preparation of the radio-labelled peptide with high specific activity and full immunogenicity. Brown, 1972) ; there was a good dose/response release.
relationship. The instillation of lipomul, a triglyf jejunal water and ceride suspension, into the duodenum evoked a rise in circulating plasma IR GIP and a reduction in acid v considered to be secretion ofthe order of 70 %. However, the hydrogen ysiological as they ion secretion returned to normal while the circulating itrations far higher GIP levels remained substantially raised. This ural stimuli. Thus, differed from the effect of intravenous GIP, after hibition and as an which acid secretion returned to control levels mmanded the most concurrently with the fall in GIP. It was suggested that the triglyceride mixture released the larger teal results in an molecular form of GIP which had no enterogastrone ntration, the peak activity (Pederson et al., 1978) .
Separation of the
The role of GIP in the inhibition of acid secretion s showed that the in man is less well understood than in dogs, and has are carbohydrates given rise to conflicting reports. One group has shown 1975). Individual that the amount of exogenous GIP required to inhibit sma concentration acid secretion after pentagastrin or a peptone meal I protein (Fig. 3) . was of pharmacological proportions (Arnold et al., 1978) , the rise in circulating GIP being some five times greater than after a meal. They concluded that although GIP may be of importance in some pathological states it was of doubtful significance in normal man. It is, of course, possible that no single factor is responsible for the physiological inhibition of acid secretion but that GIP is involved with one or more other peptides. Recently, evidence for 6 this has been adduced by Christiansen et al. (1978) n= 6 who found that the instillation offat into thejejunum caused dramatic inhibition of gastric acid secretion and a significant increase in circulating plasma levels . 'incretin' or insulin-releasing factor (La Barre, 1932) . In 1964 McIntyre made the classical observation that an oral glucose load produced a much greater insulin response than a similar dose given intravenously (McIntyre et al., 1964) . Since that time a great deal of work has been devoted to the search for the humoral factor responsible for this increased insulin response to oral carbohydrate. The realisation that the structure of GIP was similar to that of VIP, secretin, and glucagon, all of which were known to be insulin secretagogues, stimulated speculation on the role of GIP as an incretin. The fact that oral glucose elicited a prompt response of GIP, while intravenous glucose had no such effect, led Dupre et al. (1973) to investigate the insulin-releasing properties of this hormone in man. Glucose was infused intravenously with and without exogenous GIP. They reported a significant augmentation of the insulin release when glucose and GIP were infused together. Following this, many attempts have been made to establish that GIP is indeed the gastrointestinal signal for insulin release.
The insulinotropic action of GIP would appear to be demonstrable only when blood glucose is raised. For example, the ingestion of fat by fasting subjects produces a potent GIP response but no rise in plasma insulin. However, if a fat meal is given during a constant glucose infusion a large insulin release occurs pari passu with the rise in GIP. Further evidence that hyperglycaemia is necessary for the 'incretin' effect of GIP is to be found in the elegant study of Andersen et al. (1978) . These authors conclude that a blood glucose threshold mechanism to control the insulinotropic action of GIP is teleologically appropriate as it would prevent the release of large amounts of insulin at a time when there is insuficient substrate present, thereby avoiding the dangers of hypoglycaemia. While this insulinotropic effect is dependent upon raised blood glucose levels when evoked by the administration of fat or glucose, the response to amino-acid ingestion is not hyperglycaemia-dependent, and may be triggered by direct stimulation of the B-cell by the nutrients.
GIP, then, fulfils many of the criteria required for the role of 'incretin', and under the right conditions it is undoubtedly insulinotropic. In view of this, and since its role as a physiological inhibitor of acid secretion is less certain, many workers now refer to this hormone as Glucose- 
Pathology
The most striking examples of hypersecretion of gut hormones are those resulting from endocrine tumours. Although such tumours are known to secrete two members ofthesecretin-glucagonfamily of peptides, VIP and glucagon, no definite GIPoma has yet been described. The known pharmacology of GIP, however, has prompted a great deal of research into the possible role of this hormone in the aetiology of diabetes mellitus and duodenal ulcer disease.
GIP IN DIABETES MELLITUS
In view of the importance of GIP in carbohydrate metabolism, much speculation has occurred about what part, if any, it plays in diabetes mellitus. Since diabetes is characterised by a pathological oral glucose tolerance curve, often with little or no insulin response, the hyposecretion of an enteric signal could be an important facet of this disease. Measurement of the GIP response after a meal in well controlled juvenile diabetics, however, has been shown to be indistinguishable from normal (Ebert et al., 1976) . In cases of maturity onset diabetes the GIP response has been reported to be augmented after a mixed meal or oral glucose (Crockett et al., 1976) . Other workers have found this response to be raised only in obese patients (Bloom, 1976; May and Williams, 1978) . Attempts to explain this phenomenon have revolved around an insulin-GIP interrelationship.
It has been postulated that insulin exerts a negative feedback control on GIP release (Brown et al., 1975) . The augmented GIP response seen in some diabetics could thus be explained as the result of a defective feedback mechanism. An augmented GIP release has also been reported in some obese patients with hyperinsulinaemia, and it is suggested that in this circumstance the GTP cell becomes insulin resistant . In normal subjects given infusions of insulin, there is little evidence to suggest that this negative feedback control exists (Andersen et al., 1978) . The effect of insulin on GIP release in pathological circumstances may, however, be quite different.
In addition to the possible direct involvement of GIP in diabetes, another property of this hormone has been investigated, that of a glucagon secretagogue. It has been shown that infusions of GIP into diabetic subjects resulted in a significant rise in serum group.bmj.com on August 27, 2017 -Published by http://jcp.bmj.com/ Downloaded from glucagon levels. This effect was totally absent in the control group (Ross et al., 1974) . Thus, it may be an indirect action of GIP via glucagon which is reflected in pathological glucose tolerance.
GIP IN DUODENAL ULCER DISEASE
Duodenal ulcer disease is characterised by acid hypersecretion, which in turn could be the result of the hyposecretion of an inhibitory factor. Since GIP was first discovered by its acid inhibitory properties, it has been proposed as being the agent responsible for duodenal ulcer. Observations made so far have been as equivocal as those on GIP release in diabetes. The GIP response has in fact been found to be exaggerated in some patients with duodenal ulcers (Creutzfeldt et al., 1977) . This may be because of the rapid gastric emptying which often occurs in ulcer disease, as it has been shown that acid in the duodenum stimulates GIP release. This augmentation of GIP release in duodenal ulcer fits well with the increased insulin response reported in these patients.
GIP IN OTHER GASTROINTESTINAL DISORDERS
Recently, Besterman and others have investigated the release of GIP and other gastrointestinal hormones in a number of diseases which affect different segnents of the gut. As the findings are dealt with in detail by Dr Besterman on page 76, the GIP changes will only be summarised here. In coeliac disease and tropical sprue, the GIP release in response to a standard meal was greatly diminished and accompanied by a significant reduction in the insulin response (Fig. 4, 5 The part played by GIP in disease is as yet unclear. The relationships between GIP and insulin release and GIP and inhibition of acid secretion appear to be complex. For the present the assay of GIP has no obvious application in the routine laboratory. In the future, however, the measurement of GIP as a marker for upper intestinal disease, along with other hormone markers for the stomach, pancreas, and distal intestine, may well prove to be a useful tool in the diagnosis and follow-up of treatment in gastrointestinal disease.
Conclusion
Gastric inhibitory polypeptide has, in the comparatively short time since its discovery, been shown to display a wide range of pharmacological effects. The release of insulin and inhibition of gastric acid secretion may well prove to be physiological effects of this hormone. Further research into these aspects of the biology of GIP may provide valuable insights into the control of alimentary function in both health and disease.
